The ethics of early stopping rules: Who is protecting whom?

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1542-1545

  Cannistra, Stephen A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; PACLITAXEL; ANTINEOPLASTIC AGENT;

BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; ETHICS; HUMAN; LEECH; NEUROPATHY; NOTE; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RELIGION; ARTICLE; BIOASSAY; BIOMEDICAL AND BEHAVIORAL RESEARCH; CONTROLLED CLINICAL TRIAL; DECISION MAKING; FEMALE; INFORMED CONSENT; MEDICAL ETHICS; METHODOLOGY; OVARY TUMOR; PATIENT ADVOCACY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR RECURRENCE;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III; DECISION MAKING; ENDPOINT DETERMINATION; ETHICS, MEDICAL; FEMALE; HUMANS; INFORMED CONSENT; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATIENT ADVOCACY; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SURVIVAL ANALYSIS;

EID: 2442715437     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.02.150     Document Type: Note

References (8)

1. Markman M, Liu PY, Wilczynski S, et al: Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465, 2003
2. Ozols RF: Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit. J Clin Oncol 21:2451-2453, 2003
3. Thigpen T: Maybe more is better. J Clin Oncol 21:2454-2456, 2003
4. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003
5. Muss HB, Case LD, Richards F 2nd, et al: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 325:1342-1348, 1991
6. Sledge GW, Neuberg D, Bernardo P, et al: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193). J Clin Oncol 21:588-592, 2003
7. Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol 18:106-115, 2000
8. Omura GA, Brady MF, Look KY, et al: Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study. J Clin Oncol 21:2843-2848, 2003